KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Change in Acquisitions & Divestments (2020 - 2025)

Historic Change in Acquisitions & Divestments for CRISPR Therapeutics AG (CRSP) over the last 6 years, with Q3 2025 value amounting to $214.9 million.

  • CRISPR Therapeutics AG's Change in Acquisitions & Divestments fell 1322.04% to $214.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year decrease of 338.03%. This contributed to the annual value of $1.2 billion for FY2024, which is 1684.85% down from last year.
  • CRISPR Therapeutics AG's Change in Acquisitions & Divestments amounted to $214.9 million in Q3 2025, which was down 1322.04% from $310.2 million recorded in Q2 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Change in Acquisitions & Divestments ranged from a high of $419.7 million in Q3 2022 and a low of $123.0 million during Q4 2021
  • Moreover, its 5-year median value for Change in Acquisitions & Divestments was $247.7 million (2024), whereas its average is $269.7 million.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Change in Acquisitions & Divestments skyrocketed by 19420.56% in 2022 and then plummeted by 3859.59% in 2024.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Change in Acquisitions & Divestments stood at $123.0 million in 2021, then skyrocketed by 164.25% to $325.1 million in 2022, then decreased by 11.57% to $287.4 million in 2023, then rose by 29.77% to $373.0 million in 2024, then plummeted by 42.38% to $214.9 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $214.9 million for Q3 2025, versus $310.2 million for Q2 2025 and $186.2 million for Q1 2025.